Kyverna Therapeutics, located in the San Francisco East Bay, is a cell therapy company engineering a new class of therapies for serious autoimmune diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/14/20 | $25,000,000 | Series A |
Gilead Sciences Vida Ventures  Westlake Village BioPartners | undisclosed |
| 01/27/22 | $85,000,000 | Series B |
Argentum CAM Capital Gilead Sciences Healthcor Partners Hudson Bay Capital Management Insight Partners jVen Capital LYFE Capital Northpond Ventures RTW Investments Vida Ventures Westlake Village BioPartners | undisclosed |
| 08/03/23 | $60,000,000 | Series B Extension |
Bain Capital Life Sciences CAM Capital Gilead Sciences GordonMD Global Investments Insight Partners jVen Capital LYFE Capital Northpond Ventures RTW Investments Vida Ventures Westlake Village BioPartners | undisclosed |
